Results 151 to 160 of about 10,318 (317)

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management

Molecular Metabolism
Type 2 diabetes and obesity impact billions of people and the global prevalence is only growing. Current treatment options, which include pharmacotherapy, e.g., GLP-1 receptor agonists (GLP-1RA) and bariatric surgical approaches have limitations. GLY-200
Taylor L. Carlson, Mark Fineman, Stace Kernodle, Chelsea R. Hutch, Christine Bryant, Kevin Colbert, Randy J. Seeley, Ashish Nimgaonkar   +7 more
doaj   +1 more source

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy [PDF]

, 2020
Chintan V. Dave, Seoyoung C. Kim, Allison B. Goldfine, Robert J. Glynn, Angela Tong, Elisabetta Patorno   +5 more
openalex   +1 more source

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial [PDF]

, 2016
Abhishek Mishra, Bruce W. Bode, Jean-Pierre Courrèges, Louis B. Chaykin, Lucine M. Lehmann, Richard W. Simpson, Sultan Linjawi, Yehuda Handelsman   +7 more
core   +1 more source

Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias

Diabetes, Obesity and Metabolism, EarlyView.
Huilin Tang, Bingyu Zhang, Yiwen Lu, Ying Lu, Anastassia Amaro, Yuan Lu, David A. Wolk, Yong Chen   +7 more
wiley   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia

Aim: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and cardio-renal outcomes for people with type 2 diabetes (T2D).
Day, RO , de Oliveira Costa, J , Falster, MO , Greenfield, JR , Havard, A , Lin, J , Milder, TY , Neuen, BL , Pearson, SA , Stocker, SL   +9 more
core   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations

Journal of Diabetes Research
GLP-1 receptor agonists (GLP-1RAs) are extensively used in treating Type 2 diabetes due to their therapeutic benefits. However, clinical reports have highlighted adverse events, particularly the underexplored association with tumor development.
Zhenhan Li, Jun Huang, Sha Zhou, Yongan Luan, Huang Xie, Zhongpei Chen, Juan Xu, Jun Qian   +7 more
doaj   +1 more source